Compass Pathways Shares Fall 27% Ahead of Third-Quarter Update

Compass Pathways plc (CMPS) shares fell 27.31% Monday ahead of third-quarter results, a steep drop in the U.S. stock that Bitget's rCMPS tokenized product is designed to track.

The stock lost $3.16 from its Oct. 30 close to finish at $8.41 at 4 p.m. ET (21:00 UTC) on Nov. 2. It opened at $11.71 and traded between $7.54 and $11.76. The closing price was below its 20-, 50- and 200-day simple moving averages.

Bitget’s rCMPS tokenized product is built to follow Compass share prices. The exchange's tokenized U.S. stock service is unavailable to U.S. users.

COMP360 is Compass’s experimental synthetic psilocybin therapy for treatment-resistant depression. In August, the company said parts of its new drug application were under rolling review and that it expected to complete the submission in the fourth quarter of 2026.

The Food and Drug Administration (FDA) granted rolling review and selected COMP360 for its Commissioner’s National Priority Voucher pilot program in April. The treatment has not been approved.

Compass has scheduled third-quarter results and an update on recent developments for Tuesday, Nov. 3, with a management call at 8 a.m. ET (13:00 UTC).